Bio-Techne price target lowered to $99 from $111.50 at Baird

Baird analyst Catherine Schulte lowered the firm’s price target on Bio-Techne to $99 from $111.50 and keeps an Outperform rating on the shares. The analyst said while earnings and revenues came in light, this likely positions shares as more of a 2H 2023 story as we continue to favor TECH‘s portfolio/defensive exposure and potential capital deployment opportunities.